{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Indianapolis&page=79&state=Indiana",
    "query": {
      "state": "Indiana",
      "city": "Indianapolis",
      "page": 79
    },
    "page_size": 10
  },
  "pagination": {
    "page": 79,
    "page_size": 10,
    "total_count": 8625,
    "total_pages": 863,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Indianapolis&page=80&state=Indiana&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Indianapolis&page=78&state=Indiana&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T00:00:03.917Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04919512",
      "title": "A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urinary Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "TAR-200",
          "type": "DRUG"
        },
        {
          "name": "Cetrelimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 163,
      "start_date": "2022-07-07",
      "completion_date": "2026-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-19T00:00:03.917Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04919512"
    },
    {
      "nct_id": "NCT00809965",
      "title": "An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Coronary Syndrome",
        "Myocardial Infarction",
        "Myocardial Ischemia",
        "Unstable Angina"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15526,
      "start_date": "2008-11",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2014-09-17",
      "last_synced_at": "2026-11-19T00:00:03.917Z",
      "location_count": 73,
      "location_summary": "Birmingham, Alabama • Geneva, Alabama • Mobile, Alabama + 70 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Geneva",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00809965"
    },
    {
      "nct_id": "NCT00198107",
      "title": "Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Autistic Disorder"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "D-cycloserine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 81,
      "start_date": "2005-09",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2019-04-09",
      "last_synced_at": "2026-11-19T00:00:03.917Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00198107"
    },
    {
      "nct_id": "NCT03525613",
      "title": "A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "APL-2",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 637,
      "start_date": "2018-08-31",
      "completion_date": "2022-06-28",
      "has_results": true,
      "last_update_posted_date": "2023-07-06",
      "last_synced_at": "2026-11-19T00:00:03.917Z",
      "location_count": 67,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03525613"
    },
    {
      "nct_id": "NCT00198224",
      "title": "Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Renal Failure"
      ],
      "interventions": [
        {
          "name": "phlebotomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2003-01",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2005-09-20",
      "last_synced_at": "2026-11-19T00:00:03.917Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00198224"
    },
    {
      "nct_id": "NCT04649359",
      "title": "MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elranatamab (PF-06863135)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 187,
      "start_date": "2021-02-02",
      "completion_date": "2026-08-25",
      "has_results": true,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-19T00:00:03.917Z",
      "location_count": 37,
      "location_summary": "Beverly Hills, California • Irvine, California • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04649359"
    },
    {
      "nct_id": "NCT04413279",
      "title": "Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye Syndromes"
      ],
      "interventions": [
        {
          "name": "LipiFlow Thermal Pulsation",
          "type": "PROCEDURE"
        },
        {
          "name": "Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Eye Surgeons of Indiana",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2020-08-01",
      "completion_date": "2021-07-01",
      "has_results": true,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-19T00:00:03.917Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04413279"
    },
    {
      "nct_id": "NCT01889862",
      "title": "Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Phenylketonuria (PKU)"
      ],
      "interventions": [
        {
          "name": "BMN165 20mg/day",
          "type": "DRUG"
        },
        {
          "name": "BMN165 40mg/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 215,
      "start_date": "2013-07-29",
      "completion_date": "2019-02-05",
      "has_results": true,
      "last_update_posted_date": "2021-05-21",
      "last_synced_at": "2026-11-19T00:00:03.917Z",
      "location_count": 29,
      "location_summary": "La Jolla, California • Oakland, California • Aurora, Colorado + 26 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01889862"
    },
    {
      "nct_id": "NCT07173803",
      "title": "The Progressive Supranuclear Palsy Clinical Trial Platform",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Progressive Supranuclear Palsy(PSP)"
      ],
      "interventions": [
        {
          "name": "AADvac1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LM11A-31",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Adam Boxer",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "41 Years",
        "maximum_age": "86 Years",
        "sex": "ALL",
        "summary": "41 Years to 86 Years"
      },
      "enrollment_count": 440,
      "start_date": "2026-07-29",
      "completion_date": "2030-09-28",
      "has_results": false,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-19T00:00:03.917Z",
      "location_count": 24,
      "location_summary": "Sun City, Arizona • Los Angeles, California • Palo Alto, California + 18 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07173803"
    },
    {
      "nct_id": "NCT00240253",
      "title": "A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "pramlintide acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 200,
      "start_date": "2005-10",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2015-03-31",
      "last_synced_at": "2026-11-19T00:00:03.917Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Concord, California • La Jolla, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Gatos",
          "state": "California"
        },
        {
          "city": "Salinas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00240253"
    }
  ]
}